Hapvida in talks to sell assets to funds eyeing Intermédica, sources say - Valor International

Direct Source Verification: This story is aggregated from G1 Globo (globo.com). Full reporting rights and copyright belong to the primary publisher.
Hapvida is in early-stage talks with potential buyers, including private equity firms Bain, Advent, CVC, and Mubadala, about selling underperforming assets. Another name mentioned in the market as a natural potential buyer is Amil, owned by businessman José Seripieri Filho, known...

Hapvida is in early-stage talks with potential buyers, including private equity firms Bain, Advent, CVC, and Mubadala, about selling underperforming assets. Another name mentioned in the market as a natural potential buyer is Amil, owned by businessman José Seripieri Filho, known as Junior, Valor has learned.

The interest from Bain and Advent was first reported by Broadcast/Estadão.

Sources also said that the process, led by BTG, does not specifically target the company’s Southeast operations, which include NotreDame Intermédica. The Pinheiro family, which founded Hapvida, would consider selling this asset only as a last resort.

However, the crown jewel, and the asset most likely to attract the type of private equity firms being approached, which typically seek larger transactions, is the Southeast business. Hapvida has struggled to turn around its São Paulo operations and faces fierce competition from Amil, which has cut prices and is winning over some of its customers.

The company has R$5.3 billion in available cash and is financially capable of servicing its debt, but it has struggled to expand in the São Paulo market, the country’s most important healthcare market.

Sources say the Pinheiro family is strongly opposed to parting with NotreDame Intermédica, which became part of Hapvida through the merger announced in 2021 and enabled the Fortaleza-based healthcare company to expand into the Southeast.

A deal with Bain would effectively mean selling NotreDame Intermédica back to its former owner and acknowledging that Hapvida had failed to manage its Southeast operations. It would also confirm the widely discussed perception at the time of the 2021 merger that the two companies had very different corporate cultures.

Sources said the Pinheiro family’s resistance would be even stronger to a sale to Bain involving Irlau Machado, NotreDame Intermédica’s former CEO. Relations between the Pinheiro family and Machado reportedly deteriorated during the integration of Hapvida and Intermédica.

During a conference call last week to discuss its third-quarter results, Hapvida CEO Lucas Adib said the asset divestment process had been stepped up but did not disclose which markets were being targeted.

On November 11, the company announced the sale of the building housing Octaviano Neves Hospital in Belo Horizonte for R$60 million. In 2021, when Hapvida acquired a 73% stake in the operation, the hospital was valued at R$134 million.

In southern Brazil, the transaction involves the sale of healthcare operators Clinipam, which operates in Curitiba and the surrounding area, and Centro Clínico Gaúcho, based in Porto Alegre. The deal is valued at nearly R$1 billion, far below the R$4 billion invested in acquisitions and infrastructure improvements over the past five years.

In a strongly worded letter sent to the Pinheiro family and the company’s CEO in early April, investment firm Squadra, which once held a 6% stake in Hapvida, advocated selling the company’s operations in the South and Southeast regions.

The firm argued that Hapvida owns assets that could offer concrete turnaround opportunities under operators with the specific expertise and focus required for each business segment and region. Potential buyers, it said, would be better positioned to unlock value from operations that are currently deteriorating.

In response to questions from Valor, Hapvida said it “does not comment on market rumors or speculation. As presented in its third-quarter 2026 results, the company maintains an ongoing agenda focused on operational efficiency and optimization of its healthcare network. Any material transactions that may be completed will be disclosed to the market in accordance with applicable regulations.”

Amil said it was not interested in the assets in question. Advent and Mubadala declined to comment.

This article was translated from Valor Econômico using an artificial intelligence tool under the supervision of the Valor International editorial team to ensure accuracy, clarity, and adherence to our editorial standards. Read our Editorial Principles.

Original Source
https://valorinternational.globo.com/business/news/2026/11/19/hapvida-in-talks-to-sell-assets-to-funds-eyeing-intermedica-sources-say.ghtml
Visit G1 Globo ↗
SHARE STORY:
𝕏 f in

Related Coverage in Business